check_circleStudy Completed

Erectile Dysfunction

BAY38-9456, Vardenafil ODT pivotal bioequivalence 16 mg ODT

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 - 50 Years
  • -

  • -

Trial summary

Enrollment Goal
99
Trial Dates
September 2006 - November 2006
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Vardenafil ODT (BAY38-9456)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Institut für Klinische Pharmakologie, Prof. Lücker GmbHMannheim, 68167, Germany

Trial design

Randomized, open-label, two-fold crossover study to investigate the bioequivalence of vardenafil after a single dose administration of one 16 mg oral disintegrating tablet in comparison to one 20 mg commercial tablet in healthy male subjects (BAY 38-9456/11217)
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A